Diabetes medications and risk of HCC
Torres M, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022, 76: 1880-1897. PMID: 35239194, PMCID: PMC9790535, DOI: 10.1002/hep.32439.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusLiver diseaseRisk of HCCDiabetic medicationsDiabetes mellitusGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsCotransporter 2 inhibitorsAchievement of euglycemiaInsulin-sensitizing activityLiver cancer tumorigenesisDiabetes medicationsDrug armamentariumInsulin resistanceReceptor agonistRisk factorsInsulin secretionCurrent evidenceNew agentsCancer tumorigenesisGlucose absorptionEndocrinology perspectiveHepatic carcinogenesis